Efficacy and Safety of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of Demographic and Clinical Subgroups from 2 Phase 3 Randomized Placebo-Controlled Trials.
Authors: Earley WR, Durgam S, Chen C, Migliore R, Riise J, Kornstein SG, McIntyre RS, Fava M
Journal: European Psychiatry
mental health
psychology
open access